Evidence map›Paper›PMID 39085269›Full record

ReviewNature communications2024

Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.

Fiona Howroyd, Cyril Chacko, Andrew MacDuff, Nandan Gautam, Brian Pouchet, Bill Tunnicliffe, Jonathan Weblin, Fang Gao-Smith, Zubair Ahmed, Niharika A Duggal and 1 more

Abstract readReview
In one paragraph

Review in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fiona HowroydTherapy Services, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, UK. fjh722@student.bham.ac.uk.ORCID 0000-0002-2306-3376
Cyril ChackoDepartment of Critical Care Medicine and Anaesthesia, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
Andrew MacDuffDepartment of Critical Care Medicine and Anaesthesia, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
Nandan GautamCritical Care Department, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, UK.
Brian PouchetCritical Care Department, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, UK.
Bill TunnicliffeCritical Care Department, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, UK.
Jonathan WeblinTherapy Services, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, UK.
Fang Gao-SmithInstitute of Inflammation and Ageing, The University of Birmingham, Edgbaston, Birmingham, UK.
Zubair AhmedInstitute of Inflammation and Ageing, The University of Birmingham, Edgbaston, Birmingham, UK. z.ahmed.1@bham.ac.uk.ORCID 0000-0001-6267-6442
Niharika A DuggalInstitute of Inflammation and Ageing, The University of Birmingham, Edgbaston, Birmingham, UK. n.arora@bham.ac.uk.
Tonny VeenithDepartment of Critical Care Medicine and Anaesthesia, The Royal Wolverhampton NHS Trust, Wolverhampton, UK. tonny.veenith1@nhs.net.ORCID 0000-0002-4125-8804

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ventilator-associated pneumonia (VAP) affects up to 20% of critically ill patients and induces significant antibiotic prescription pressure, accounting for half of all antibiotic use in the ICU. VAP significantly increases hospital length of stay and healthcare costs yet is also associated with long-term morbidity and mortality. The diagnosis of VAP continues to present challenges and pitfalls for the currently available clinical, radiological and microbiological diagnostic armamentarium. Biomarkers and artificial intelligence offer an innovative potential direction for ongoing future research. In this Review, we summarise the pathobiological heterogeneity and diagnostic challenges associated with VAP.

Indexed as

Pneumonia, Ventilator-AssociatedAnti-Bacterial AgentsBiomarkersCritical IllnessHumansIntensive Care UnitsLength of StayAnti-Bacterial AgentsBiomarkers

Identifiers

PMID39085269
PMCPMC11291905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.